Mulhem, 3,219 patient aspirin prophylaxis study: 14% higher mortality [p=0.21] https://c19p.org/mulheme
copied to clipboard
3219 hospitalised patients with COVID-19 in Southeast Michigan: a retrospective case cohort study
et al., BMJ Open, doi:10.1136/bmjopen-2020-042042
Retrospective database analysis of 3,219 hospitalized patients in the USA. Very different results in the time period analysis (Table S2), and results significantly different to other studies for the same medications (e.g., heparin OR 3.06 [2.44-3.83]) suggest significant confounding by indication and confounding by time.
|
risk of death, 13.9% higher, RR 1.14, p = 0.21, treatment 300 of 1,354 (22.2%), control 216 of 1,865 (11.6%), adjusted per study, odds ratio converted to relative risk, Table S1, logistic regression.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted confounding by indication likely, substantial confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically.
Mulhem et al., 4/7/2021, retrospective, database analysis, USA, North America, peer-reviewed, 3 authors.
mulhem
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.